Y-39983

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameY-39983
Drug Alias NameY39983RKI-983SNJ-1656
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRhodopsin kinase inhibitors
TargetsRhodopsin kinase
Therapy Area/IndicationsGlaucomaOcular Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMitsubishi Tanabe Pharma
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsGlaucomaOcular Hypertension

Other Information

ATC CodeN/A
Related LinksN/A